Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Evaluation of a Pharmacist-Integrated Model of Opioid Use Disorder Treatment to Increase Naloxone Co-Prescribing in Primary Care

Award Number: F31DA060690
ORGANIZATION: NATIONAL INSTITUTE ON DRUG ABUSE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: FELLOWSHIP/SCHOLARSHIP/STUDENT LOANS
PERIOD OF PERFORMANCE START DATE: 06/01/2024
PERIOD OF PERFORMANCE END DATE: 05/31/2025
AWARD TERMINATION DATE: 05/15/2025

Group Awards By:

View Award Description

Evaluation of a Pharmacist-Integrated Model of Opioid Use Disorder Treatment to Increase Naloxone Co-Prescribing in Primary Care - PROJECT SUMMARY In the United States overdose deaths remain at near record highs, largely due to the proliferation of fentanyl in the illicit opioid supply. Increasing access to the opioid overdose antidote, naloxone, to people at high risk of experiencing or witnessing an overdose is a public health intervention shown to reduce overdose death. Nearly half of the US states have a provision related to prescribing naloxone to patients at risk, namely patients prescribed medication for opioid use disorder, known as co-prescription. However, research suggests most states are not distributing or co-prescribing enough naloxone to prevent 80% of witnessed overdose deaths. While the most recent federal approval of the first over-the counter (OTC) naloxone formulation will help increase access for people who can afford OTC naloxone, it is unknown how this approval may affect access for people receiving medication treatment for OUD in primary care. Co-prescribing naloxone in primary care has the potential to fill what has been a persistent gap in the overdose crisis response. There is growing literature that pharmacists can help to increase naloxone co-prescription. The NIDA Clinical Trials Network 0116 study (PI: Marsch) is ongoing and aims to evaluate the feasibility, acceptability, and impact of implementing a pharmacist-integrated model of medication treatment for OUD (PrIMO) in four primary care sites in four states. The objective of this F31 application is to investigate whether PrIMO may increase primary care capacity for co-prescribing naloxone within the parent study. The research project aims to: (1) Describe federal, state, and clinic-level policies and current OUD interventions which impact co-prescribing naloxone within four PrIMO primary care sites in four states. (2) Investigate care team knowledge and attitudes regarding naloxone, emerging OTC naloxone guidance, and patient overdose across PrIMO implementation, and (3) Evaluate naloxone co-prescribing to patients receiving medication treatment for OUD by patient demographics, provider type, health insurance, urine drug test results, and (b) test if these associations become stronger or weaker across PrIMO implementation. The training plan outlines four learning objectives: (1) gaining descriptive and historical knowledge of the breadth of naloxone policies across different states in the U.S, (2) proficiency with performing longitudinal qualitative interviews with participants as well as proficiency with qualitative analysis techniques relevant to clinical trial implementation and evaluation. (3) proficiency with multi- level modeling relevant to primary care electronic medical record data and (4) developing as a professional academic scientist. These objectives will be achieved with the support and commitment of the mentor, consultant team, and institution. This proposal supports the applicants long-term research agenda to reduce opioid overdose deaths by facilitating greater access to naloxone and evidence-based models of OUD care.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = -$1 )
2026	2024	TRUSTEES OF DARTMOUTH COLLEGE	7 LEBANON ST	HANOVER	NH	03755	GRAFTON	USA	Drug Use and Addiction Research Programs	000	1	3/24/2026	TERMINATION	-$1
														Subtotal = -$1

Issue Date FY: 2025 ( Subtotal = $0 )
2025	2024	TRUSTEES OF DARTMOUTH COLLEGE	7 LEBANON ST	HANOVER	NH	03755	GRAFTON	USA	Drug Use and Addiction Research Programs	000	1	5/5/2025	TERMINATION	$0
														Subtotal = $0

Issue Date FY: 2024 ( Subtotal = $48,974 )
2024	2024	TRUSTEES OF DARTMOUTH COLLEGE	7 LEBANON ST	HANOVER	NH	03755	GRAFTON	USA	Drug Use and Addiction Research Programs	002	1	5/1/2024	NEW	$1,280
2024	2024	TRUSTEES OF DARTMOUTH COLLEGE	7 LEBANON ST	HANOVER	NH	03755	GRAFTON	USA	Drug Use and Addiction Research Programs	001	1	3/25/2024	NEW	$0
2024	2024	TRUSTEES OF DARTMOUTH COLLEGE	7 LEBANON ST	HANOVER	NH	03755	GRAFTON	USA	Drug Use and Addiction Research Programs	000	1	3/25/2024	NEW	$47,694
														Subtotal = $48,974

Grand Total All Awards = $48,973

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Evaluation of a Pharmacist-Integrated Model of Opioid Use Disorder Treatment to Increase Naloxone Co-Prescribing in Primary Care

Award Number: F31DA060690

ORGANIZATION: NATIONAL INSTITUTE ON DRUG ABUSE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: FELLOWSHIP/SCHOLARSHIP/STUDENT LOANS

PERIOD OF PERFORMANCE START DATE: 06/01/2024

PERIOD OF PERFORMANCE END DATE: 05/31/2025

AWARD TERMINATION DATE: 05/15/2025

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer